2024-10-25 - Analysis Report
## Merck & Co Inc (MRK) Stock Analysis Report

**1. Performance Comparison:**

Merck & Co Inc (MRK) has underperformed the S&P 500 (VOO) significantly. While MRK's cumulative return is 64.51%, the S&P 500 has achieved 135.48%. This results in a substantial gap of -70.97%, placing MRK at the 14.47th percentile of its historical performance range relative to the S&P 500. 

**Company Overview:** Merck & Co Inc is a global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of prescription medicines and vaccines.

**2. Recent Price Movement:**

MRK's current closing price is $105.88 (Post-market: $105.89). The 5-day moving average sits at $106.69, while the 20-day and 60-day moving averages are $109.77 and $113.59 respectively. This indicates a recent downward trend in the stock price, with the current price below all three moving averages.

**3. Technical Indicators:**

* **RSI (33.75):** The RSI value suggests that MRK is currently in oversold territory, indicating a potential for a short-term rebound. 
* **PPO (-0.26):** The negative PPO value indicates that the stock price momentum is weak and declining.
* **Delta_Previous_Relative_Divergence (-11.7):** This negative value signifies a short-term downward trend in the relative divergence, confirming the overall bearish market sentiment.
* **Expected_Return (0.0%):** Over a long-term horizon (2+ years), MRK is expected to generate similar returns as the S&P 500, suggesting a lack of significant outperformance potential.

**4. Recent Earnings and Outlook:**

| Date       | EPS  | Revenue      |
|------------|------|--------------|
| 2024-08-05 | 2.15 | 16.11 B$    |
| 2024-05-03 | 1.88 | 15.78 B$    |
| 2023-11-03 | 1.87 | 15.96 B$    |
| 2023-08-07 | -2.35 | 15.04 B$    |
| 2024-08-05 | -2.35 | 15.04 B$    |

The latest earnings report for 2024-08-05 showed an EPS of $2.15, exceeding analysts' expectations. However, the company's revenue growth has slowed down, with the current quarter's revenue slightly lower than the previous quarter. Overall, while the latest earnings report was positive, the slowing revenue growth raises concerns about future performance.

**5. News and Recent Issues:**

* **Recent Earnings Announcement (ShackleNews, etc.):** Search for recent articles on ShackleNews or other financial news platforms related to Merck's latest earnings release for an in-depth analysis of the earnings call and analyst commentary.
* **Market Outlook:** Seek market outlooks for MRK on financial websites like Finbold. These analyses can provide insights into the stock's future performance based on market trends, industry factors, and expert opinions.
* **Analyst Opinions:**  Explore analyst ratings and price targets for MRK on websites like Finbold. This information can help gauge market sentiment and expectations for the stock's future performance.

**6. Comprehensive Analysis:**

MRK is currently underperforming the S&P 500 with a significant gap in returns. The stock price has been trending downwards recently, with technical indicators showing a weak momentum and oversold condition.  While the latest earnings exceeded expectations, the slowing revenue growth raises concerns about future performance.  

**7. Overall Recommendations:**

Based on the current analysis, MRK appears to be a relatively risky investment.  Despite a recent strong earnings report, its underperformance compared to the broader market, the slowing revenue growth, and the lack of significant long-term outperformance potential suggest a cautious approach. Investors should consider further research, focusing on market trends and analyst opinions, to form a more informed investment decision. 
